ClinicalTrials.gg
RecruitingNCT05656820BESTUpdated Nov 22, 2023

Bicuspid Echocardiac Study Team(BEST)

An observational study in Bicuspid Aortic Valve Disease, sponsored by Suzhou Municipal Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2023-11-22.

Sponsored by Suzhou Municipal Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Sex
All
01

Study summary

The Chinese Bicuspid Aortic Valve (BAV) Ultrasound imaging cohort study is a Chinese BAV ultrasound imaging cohort study. At present, a retrospective study cohort involving more than 30 hospitals has been established. The prospective multi-center study of BAV is expected to include and follow up 200 outpatients and inpatients with BAV. The clinical, ultrasound imaging and treatment parameters of the patients are collected and the patients are followed up for 2 years. To analyze the prognostic characteristics of BAV patients and establish a Chinese BAV database. The primary endpoint was all-cause death, and the secondary endpoints were heart failure, angina, severe aortic stenosis, severe aortic insufficiency, ascending aortic diameter ≥50mm, and surgery (surgical and interventional). According to the different pathological types of aortic valve in different types of BAV, ultrasound imaging was used to evaluate the different forms of valvular leaflet lesions and prognosis. Finally, it provides a basis for the prognosis, treatment method, treatment timing and treatment plan selection of BAV patients, and lays a foundation for the mechanism study of BAV arterial lesions and the establishment of risk model for the prognosis of BAV patients.

02

Conditions studied

  • Bicuspid Aortic Valve Disease
03

In context

Bicuspid Aortic Valve Disease

62 studies on the registry are indexed under Bicuspid Aortic Valve Disease; 21 are open to participants now.

This study's planned enrollment of 200 is below the median of 236 across 38 observational studies indexed under Bicuspid Aortic Valve Disease.

Browse Bicuspid Aortic Valve Disease studies →

Lead sponsor

Suzhou Municipal Hospital is the lead sponsor of 9 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Outpatient, inpatient, physical examination or community referral patients.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ultrasound or other imaging tests to diagnose patients with BAV

Exclusion criteria

Exclusion Criteria:

  • Patients with TAV or/and have significant aortic valve calcification
  • Those deemed unsuitable for enrollment by clinicians (e.g., end-stage patients, mentally ill patients, non-cooperating patients, etc.)
  • Those who do not agree to be included
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Diameter of ascending aorta

    Diameter of ascending aorta shall be taken using leading edge-to-leading edge convention at end diastole.

    Time frame: baseline; once a year; through study completion.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2022 (actual). Primary completion is estimated for Dec 2023, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2022
First posted
Dec 19, 2022
StartActual
Jul 1, 2022
Primary completionEst.
Dec 30, 2023
CompletionEst.
Dec 31, 2023
Last update
Nov 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05656820
Lead sponsor
Suzhou Municipal Hospital
Responsible party
Mo Zhou (Attending physician, Suzhou Municipal Hospital) — Principal investigator
First posted
Dec 19, 2022
Start date
Jul 1, 2022
Primary completion
Dec 30, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Nov 22, 2023

Study contacts

Ya Yang
Contact
echoyangya99@163.com
+86 18911662958

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion